PMID- 33832087
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20230103
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 100
IP  - 14
DP  - 2021 Apr 9
TI  - Long-term survival in an acute promyelocytic leukemia patient with recurrent 
      granulocytic sarcomas: A case report.
PG  - e25257
LID - 10.1097/MD.0000000000025257 [doi]
LID - e25257
AB  - RATIONALE: Granulocytic sarcoma (GS) is an extramedullary myeloid tumor composed 
      of immature cells of the granulocytic series. It rarely occurs in acute 
      promyelocytic leukemia (APL). No case of long-term survival in an APL patient 
      with recurrent GS has been reported. PATIENT CONCERNS: A 54-year-old female 
      patient was diagnosed with APL in 1995 and has been in complete remission (CR) of 
      bone marrow morphology for 24 years; however, recurrent GS occurred successively 
      in ovary, breast, spine, body of sternum, lymph nodes, soft tissues from 2004 to 
      2019. DIAGNOSES: The immunohistochemistry confirmed the diagnosis of GS, and 
      fluorescence in situ hybridization (FISH) revealed its origin from APL. 
      INTERVENTIONS: She received surgery, and had an excellent response to all-trans 
      retinoic acid (ATRA), DA (daunorubicin combined with cytarabine) regimens, and 
      arsenic trioxide (ATO). OUTCOMES: The patient achieved CR in March 2020 after 
      radiotherapy followed by ATO and ATRA. So far, she is still in follow-up. 
      LESSONS: It is rare that recurrent GS at multiple sites is involved in APL 
      patient with bone marrow morphology in CR. It is interesting to observe a 
      long-term excellent response to ATRA, chemotherapy and ATO. Although multiple 
      recurrence of GS in patients with APL is rare, the data in this case highlight 
      the need for individualized treatment when such conditions occur.
CI  - Copyright (c) 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Zhou, Xuehui
AU  - Zhou X
AD  - Department of Hematology, PLA Strategic Support Force Medical Center, Beijing.
FAU - Li, Chengwen
AU  - Li C
AD  - Department of Pathology, Institute of Hematology and Blood Diseases Hospital, 
      Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 
      China.
LA  - eng
GR  - 19ZX51/PLA Strategic Support Force Medical Center/
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 5688UTC01R (Tretinoin)
SB  - IM
MH  - Female
MH  - Humans
MH  - Leukemia, Promyelocytic, Acute/*drug therapy/pathology
MH  - Middle Aged
MH  - Remission Induction
MH  - Sarcoma, Myeloid/*drug therapy/pathology
MH  - Tretinoin/*therapeutic use
PMC - PMC8036079
COIS- The authors declare no conflicts of interest.
EDAT- 2021/04/10 06:00
MHDA- 2021/04/20 06:00
PMCR- 2021/04/09
CRDT- 2021/04/09 01:00
PHST- 2020/11/12 00:00 [received]
PHST- 2021/03/04 00:00 [accepted]
PHST- 2021/04/09 01:00 [entrez]
PHST- 2021/04/10 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
PHST- 2021/04/09 00:00 [pmc-release]
AID - 00005792-202104090-00031 [pii]
AID - MD-D-20-10921 [pii]
AID - 10.1097/MD.0000000000025257 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2021 Apr 9;100(14):e25257. doi: 
      10.1097/MD.0000000000025257.